Skip to main content
Top
Published in: Clinical Rheumatology 8/2014

01-08-2014 | Original Article

Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?

Authors: Yuen Ling Elaine Au, Woon Sing Raymond Wong, Mo Yin Mok, Ho Yin Chung, Eric Chan, Chak Sing Lau

Published in: Clinical Rheumatology | Issue 8/2014

Login to get access

Abstract

Recently, the Ankylosing Spondylitis Disease Activity Score (ASDAS), a new index, has been shown to be validated and highly discriminatory in assessing ankylosing spondylitis (AS) disease activity. This study is to evaluate the performance of ASDAS in a local Chinese cohort of AS in a cross-sectional setting and to compare it with the existing instrument, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Consecutive patients with AS were recruited from a local rheumatology clinic. Data, including BASDAI, Bath Ankylosing Spondylitis Functional Index (BASFI), Visual Analogue Scale (VAS) for spinal pain, and patient and physician global assessments were gathered during clinic visit. Inflammatory markers, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and high-sensitivity (hs)-CRP were collected. ASDAS was calculated accordingly. The discriminatory capacity of BASDAI and ASDAS was compared by: (1) standardized mean difference statistics, (2) R 2 in linear regressions, and (3) area under receiver operating characteristic curve (AUC) in logistic regression models. Both ASDAS and BASDAI showed satisfactory predictive value on disease activity with reference to patient and physician global assessment. R 2 in linear regression models ranged from 0.6–0.7. Both indices also demonstrated good discriminatory capacity as evidenced by a relatively high AUC (> 0.8) under the logistic regression models using either patient or physician global assessment score ≥4 and <4 as cut off of high and low disease activity status, respectively. Although we could not demonstrate significant differences in the performance between them, subgroup analysis suggested better discriminatory ability of ASDAS in the high inflammatory marker subgroup. ASDAS and BASDAI showed similarly good performance in a cross-sectional setting in a local Chinese AS cohort. ASDAS performed better in subgroup with raised inflammatory markers.
Literature
1.
go back to reference Haywood KL, Garratt AM, Dawes PT (2005) Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford) 44(5):577–586CrossRef Haywood KL, Garratt AM, Dawes PT (2005) Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford) 44(5):577–586CrossRef
2.
go back to reference Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 38(9):878–882CrossRef Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 38(9):878–882CrossRef
3.
go back to reference Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68(1):18–24PubMedCrossRef Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68(1):18–24PubMedCrossRef
4.
go back to reference van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68(12):1811–1818PubMedCrossRef van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68(12):1811–1818PubMedCrossRef
5.
go back to reference Wei JC, Wong RH, Huang JH, Yu CT, Chou CT, Jan MS et al (2007) Evaluation of internal consistency and re-test reliability of Bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan. Clin Rheumatol 26(10):1685–1691PubMedCrossRef Wei JC, Wong RH, Huang JH, Yu CT, Chou CT, Jan MS et al (2007) Evaluation of internal consistency and re-test reliability of Bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan. Clin Rheumatol 26(10):1685–1691PubMedCrossRef
6.
go back to reference Nas K, Yildirim K, Cevik R, Karatay S, Erdal A, Baysal O et al (2010) Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis 13(3):240–245PubMedCrossRef Nas K, Yildirim K, Cevik R, Karatay S, Erdal A, Baysal O et al (2010) Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis 13(3):240–245PubMedCrossRef
7.
go back to reference Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70(1):47–53PubMedCrossRef Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70(1):47–53PubMedCrossRef
8.
go back to reference Sheehan NJ, Slavin BM, Donovan MP, Mount JN, Mathews JA (1986) Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 25(2):171–174PubMedCrossRef Sheehan NJ, Slavin BM, Donovan MP, Mount JN, Mathews JA (1986) Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 25(2):171–174PubMedCrossRef
9.
go back to reference Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26(4):966–970PubMed Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26(4):966–970PubMed
10.
go back to reference Spoorenberg A, van Tubergen A, Landewe R, Dougados M, van der Linden S, Mielants H et al (2005) Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) 44(6):789–795CrossRef Spoorenberg A, van Tubergen A, Landewe R, Dougados M, van der Linden S, Mielants H et al (2005) Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) 44(6):789–795CrossRef
11.
go back to reference Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984PubMed Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984PubMed
12.
go back to reference Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H, Veys E et al (1999) Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 26(4):971–974PubMed Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H, Veys E et al (1999) Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 26(4):971–974PubMed
13.
go back to reference Eder L, Chandran V, Shen H, Cook RJ, Gladman DD (2010) Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 69(12):2160–2164PubMedCrossRef Eder L, Chandran V, Shen H, Cook RJ, Gladman DD (2010) Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 69(12):2160–2164PubMedCrossRef
14.
go back to reference Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670PubMedCentralPubMedCrossRef Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670PubMedCentralPubMedCrossRef
15.
go back to reference Stone MA, Payne U, Pacheco-Tena C, Inman RD (2004) Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 63(1):84–87PubMedCentralPubMedCrossRef Stone MA, Payne U, Pacheco-Tena C, Inman RD (2004) Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 63(1):84–87PubMedCentralPubMedCrossRef
16.
go back to reference Davis JC Jr, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO et al (2005) Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 32(9):1751–1754PubMed Davis JC Jr, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO et al (2005) Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 32(9):1751–1754PubMed
17.
go back to reference Luc M, Gossec L, Ruyssen-Witrand A, Salliot C, Duclos M, Guignard S et al (2007) C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis. J Rheumatol 34(10):2078–2081PubMed Luc M, Gossec L, Ruyssen-Witrand A, Salliot C, Duclos M, Guignard S et al (2007) C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis. J Rheumatol 34(10):2078–2081PubMed
18.
go back to reference de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA et al (2009) Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 61(11):1484–1490PubMedCrossRef de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA et al (2009) Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 61(11):1484–1490PubMedCrossRef
19.
go back to reference Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML (2010) Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 69(11):2002–2008PubMedCrossRef Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML (2010) Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 69(11):2002–2008PubMedCrossRef
Metadata
Title
Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?
Authors
Yuen Ling Elaine Au
Woon Sing Raymond Wong
Mo Yin Mok
Ho Yin Chung
Eric Chan
Chak Sing Lau
Publication date
01-08-2014
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 8/2014
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2729-5

Other articles of this Issue 8/2014

Clinical Rheumatology 8/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine